What is InspireMD's operating income?

InspireMD's total operating income in 2025 was -$49.61 million, based on the following breakdown: Total Gross Profit: $2.65 million Total Operating Expenses: $52.26 million

InspireMD (NSPR) Financials

$0.71 -0.01 (-1.38%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$0.70 -0.01 (-0.86%)

As of 07/16/2026 06:38 PM Eastern

Compare

Annual Income Statements for InspireMD

This table shows InspireMD's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-16	-8.46	-7.81	-7.98	-10	-11	-15	-18	-20	-32	-49
Consolidated Net Income / (Loss)	-16	-8.46	-8.44	-7.24	-10	-11	-15	-18	-20	-32	-49
Net Income / (Loss) Continuing Operations	-16	-8.46	-8.44	-7.98	-10	-11	-15	-18	-20	-32	-49
Total Pre-Tax Income	-16	-8.46	-8.41	-7.24	-10	-11	-15	-18	-20	-32	-49
Total Operating Income	-14	-7.65	-8.23	-7.61	-9.82	-10	-15	-19	-21	-34	-50
Total Gross Profit	-0.30	0.10	0.59	1.00	0.76	0.08	0.75	1.12	1.81	1.51	2.65
Total Revenue	2.31	1.89	2.76	3.60	3.72	2.49	4.50	5.17	6.21	7.01	8.98
Operating Revenue	2.31	1.89	2.76	3.60	3.72	2.49	4.50	5.17	6.21	7.01	8.98
Total Cost of Revenue	2.61	1.79	2.18	2.61	2.97	2.40	3.74	4.05	4.40	5.50	6.33
Operating Cost of Revenue	2.61	1.79	2.18	2.61	2.97	2.40	3.74	4.05	4.40	5.50	6.33
Total Operating Expenses	14	7.75	8.82	8.61	11	10	15	20	23	35	52
Selling, General & Admin Expense	6.39	5.00	5.18	4.83	5.22	6.13	7.41	8.36	11	15	21
Marketing Expense	3.18	1.46	2.36	2.24	2.40	2.10	2.91	3.66	3.87	6.07	17
Research & Development Expense	3.64	1.29	1.28	1.54	2.95	2.23	5.16	7.81	7.98	14	15
Total Other Income / (Expense), net	-1.10	-0.81	-0.18	-0.37	-0.20	-0.16	-0.16	0.25	1.29	1.56	0.89
Other Income / (Expense), net	-0.06	-0.09	-0.06	0.37	-0.20	-	-	0.25	1.29	1.56	0.89
Income Tax Expense	0.00	0.00	0.03	0.00	0.02	0.00	0.05	0.03	0.07	0.06	0.06
Basic Earnings per Share	($55.85)	($207.72)	($34.98)	($16.67)	($4.80)	($6.97)	($2.03)	($2.35)	($0.82)	($0.76)	($0.76)
Weighted Average Basic Shares Outstanding	279.06K	40.73K	372.46K	461.54K	2.09M	1.51M	7.35M	7.87M	24.27M	41.93M	64.33M
Diluted Earnings per Share	($55.85)	($207.72)	($34.98)	($16.67)	($4.80)	($6.97)	-	($2.35)	($0.82)	($0.76)	($0.76)
Weighted Average Diluted Shares Outstanding	279.06K	40.73K	372.46K	461.54K	2.09M	1.51M	7.35M	7.87M	24.27M	41.93M	64.33M
Weighted Average Basic & Diluted Shares Outstanding	279.06K	40.73K	372.46K	461.54K	2.09M	1.51M	7.35M	8.33M	23.46M	29.69M	46.80M

This table shows InspireMD's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-5.18	-5.41	-7.03	-7.91	-7.89	-9.17	-11	-13	-13	-12	-14
Consolidated Net Income / (Loss)	-5.18	-5.41	-7.03	-7.91	-7.89	-9.17	-11	-13	-13	-12	-14
Net Income / (Loss) Continuing Operations	-5.18	-5.41	-7.03	-7.91	-7.89	-9.17	-11	-13	-13	-12	-14
Total Pre-Tax Income	-5.18	-5.34	-7.03	-7.91	-7.89	-9.12	-11	-13	-13	-12	-14
Total Operating Income	-5.64	-5.81	-7.41	-8.26	-8.46	-9.37	-11	-13	-13	-12	-14
Total Gross Profit	0.44	0.51	0.29	0.33	0.41	0.47	0.29	0.31	0.86	1.18	0.69
Total Revenue	1.56	1.76	1.51	1.74	1.81	1.95	1.53	1.78	2.52	3.15	3.40
Operating Revenue	1.56	1.76	1.51	1.74	1.81	1.95	1.53	1.78	2.52	3.15	3.40
Total Cost of Revenue	1.12	1.26	1.22	1.41	1.40	1.48	1.24	1.47	1.66	1.97	2.71
Operating Cost of Revenue	1.12	1.26	1.22	1.41	1.40	1.48	1.24	1.47	1.66	1.97	2.71
Total Operating Expenses	6.08	6.31	7.71	8.59	8.88	9.84	12	13	14	13	15
Selling, General & Admin Expense	3.09	2.97	3.84	3.75	3.49	4.23	4.94	5.33	5.89	4.55	4.72
Marketing Expense	0.88	1.31	1.24	1.45	1.47	1.92	2.75	4.17	4.39	5.24	5.18
Research & Development Expense	2.11	2.04	2.63	3.40	3.92	3.69	4.06	3.83	3.64	3.48	4.76
Total Other Income / (Expense), net	0.46	0.47	0.38	0.35	0.57	0.25	0.29	-0.13	0.34	0.39	0.29
Other Income / (Expense), net	0.46	0.47	0.38	0.35	0.57	0.25	0.29	-0.13	0.34	0.39	0.29
Basic Earnings per Share	($0.15)	$0.10	($0.21)	($0.22)	($0.16)	($0.17)	$0.22	($0.26)	($0.17)	($0.11)	($0.16)
Weighted Average Basic Shares Outstanding	33.98M	24.27M	34.24M	35.88M	48.37M	41.93M	49.99M	51.00M	73.47M	64.33M	83.80M
Diluted Earnings per Share	($0.15)	$0.10	($0.21)	($0.22)	($0.16)	($0.17)	$0.22	($0.26)	($0.17)	($0.11)	($0.16)
Weighted Average Diluted Shares Outstanding	33.98M	24.27M	34.24M	35.88M	48.37M	41.93M	49.99M	51.00M	73.47M	64.33M	83.80M
Weighted Average Basic & Diluted Shares Outstanding	21.55M	23.46M	24.93M	25.71M	26.08M	29.69M	30.64M	41.72M	42.37M	46.80M	46.84M

This table details how cash moves in and out of InspireMD's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-3.04	4.26	-3.81	5.67	-3.86	7.13	-0.64	-7.37	5.01	9.28	-9.98
Net Cash From Operating Activities	-12	-7.50	-8.13	-7.61	-9.81	-9.08	-13	-16	-16	-22	-35
Net Cash From Continuing Operating Activities	-12	-7.50	-7.69	-7.61	-9.81	-9.08	-13	-16	-16	-22	-35
Net Income / (Loss) Continuing Operations	-16	-8.46	-8.44	-7.24	-10	-11	-15	-18	-20	-32	-49
Consolidated Net Income / (Loss)	-16	-8.46	-8.44	-7.24	-10	-11	-15	-18	-20	-32	-49
Depreciation Expense	0.24	0.19	0.18	0.15	0.16	0.15	0.16	0.19	0.23	0.28	0.48
Non-Cash Adjustments To Reconcile Net Income	2.39	0.37	0.66	-0.34	0.49	1.80	1.61	2.42	4.04	9.12	12
Changes in Operating Assets and Liabilities, net	1.36	0.40	-0.10	-0.18	-0.42	-0.49	-0.06	0.34	-0.71	0.74	1.11
Net Cash From Investing Activities	-0.02	0.07	-0.32	-0.04	-0.39	-0.19	-22	8.44	-16	13	-31
Net Cash From Continuing Investing Activities	-0.02	0.07	-0.32	-0.04	-0.39	-0.19	-22	8.44	-16	13	-31
Purchase of Property, Plant & Equipment	-0.02	-0.05	-0.26	-0.07	-0.28	-0.09	-0.34	-0.47	-0.38	-1.40	-1.66
Purchase of Investments	-	-	-	-	-	0.00	-24	-19	-40	-15	-57
Sale of Property, Plant & Equipment	-	-	-	-	0.00	0.02	-	0.00	0.01	0.00	0.02
Sale and/or Maturity of Investments	-	-	-	-	-	0.00	2.00	28	25	29	28
Other Investing Activities, net	-0.01	0.12	-0.06	0.02	-0.10	-0.12	-0.11	-0.09	-0.08	-0.09	0.28
Net Cash From Financing Activities	8.62	12	4.63	13	6.34	16	35	-0.14	38	18	56
Net Cash From Continuing Financing Activities	8.62	12	4.63	13	6.34	16	35	-0.14	38	18	56
Issuance of Debt	-	-	-	-	-	-	-	-	38	1.60	39
Other Financing Activities, net	-0.11	-0.01	-0.01	-	6.34	-	0.00	-0.14	-	17	17
Effect of Exchange Rate Changes	-0.04	-0.02	-	-0.05	-	0.00	-0.01	-0.13	-0.06	0.05	0.12

This table details how cash moves in and out of InspireMD's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	2.29	-4.20	-0.25	19	-13	3.10	-6.53	-0.87	52	-54	2.42
Net Cash From Operating Activities	-4.04	-4.18	-5.06	-4.35	-5.70	-6.75	-8.79	-8.33	-8.63	-9.35	-12
Net Cash From Continuing Operating Activities	-4.04	-4.16	-5.06	-4.35	-5.70	-6.75	-8.79	-8.33	-8.63	-9.35	-12
Net Income / (Loss) Continuing Operations	-5.18	-5.41	-7.03	-7.91	-7.89	-9.17	-11	-13	-13	-12	-14
Consolidated Net Income / (Loss)	-5.18	-5.41	-7.03	-7.91	-7.89	-9.17	-11	-13	-13	-12	-14
Depreciation Expense	0.06	0.06	0.07	0.07	0.07	0.08	0.10	0.11	0.13	0.14	0.15
Non-Cash Adjustments To Reconcile Net Income	1.53	1.23	2.39	2.51	2.10	2.11	2.82	3.47	3.25	2.56	2.26
Changes in Operating Assets and Liabilities, net	-0.45	-0.05	-0.49	0.98	0.02	0.24	-0.54	1.24	0.70	-0.29	-1.06
Net Cash From Investing Activities	6.39	-0.04	4.82	5.51	-5.92	8.24	1.70	5.32	7.55	-45	15
Net Cash From Continuing Investing Activities	6.39	-0.04	4.82	5.51	-5.92	8.24	1.70	5.32	7.55	-45	15
Purchase of Property, Plant & Equipment	-0.10	-0.22	-0.20	-0.48	-0.42	-0.31	-0.36	-0.58	-0.33	-0.40	-0.19
Purchase of Investments	-	-5.81	-1.96	-	-12	-0.43	-6.91	-4.84	-	-45	0.00
Sale and/or Maturity of Investments	6.50	6.00	7.00	6.00	7.00	9.00	9.00	11	7.89	-	15
Other Investing Activities, net	-0.02	-0.02	-0.03	-0.02	-0.02	-0.02	-0.03	-0.02	-0.02	0.35	-0.03
Net Cash From Financing Activities	-	-	0.00	18	-0.97	1.56	0.51	2.14	53	-	0.00
Net Cash From Continuing Financing Activities	-	-	0.00	18	-0.97	1.56	0.51	2.14	53	-	0.00
Issuance of Common Equity	-38	-	0.00	-	0.04	-	0.51	0.19	38	-	0.00
Effect of Exchange Rate Changes	-0.05	0.01	-0.00	-0.01	0.02	0.04	0.05	-	0.05	0.02	-0.02

This table presents InspireMD's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	5.69	9.41	6.11	12	9.88	18	40	25	48	47	69
Total Current Assets	4.63	8.63	5.16	11	7.81	15	37	21	44	41	61
Cash & Equivalents	3.26	7.52	3.71	9.38	5.51	13	12	4.63	9.64	19	8.94
Short-Term Investments	-	-	-	-	-	-	-	0.00	29	16	45
Note & Lease Receivable	0.14	0.20	0.21	0.10	0.15	0.15	0.17	0.21	0.65	0.68	0.40
Accounts Receivable	0.41	0.36	0.64	0.72	0.82	0.48	1.22	1.03	1.80	1.57	2.17
Inventories, net	0.75	0.50	0.53	1.13	1.24	1.42	1.14	1.62	2.11	2.57	3.40
Prepaid Expenses	0.08	0.07	0.06	0.08	0.09	0.33	0.52	0.66	0.58	1.06	1.30
Plant, Property, & Equipment, net	0.47	0.38	0.48	0.42	0.55	0.45	0.63	0.92	1.06	2.37	3.58
Total Noncurrent Assets	0.59	0.40	0.48	0.45	1.52	1.99	1.99	2.41	2.42	3.92	4.35
Employee Benefit Assets	0.50	0.40	0.48	0.45	0.59	0.73	0.91	0.86	0.95	1.13	1.15
Other Noncurrent Operating Assets	0.09	-	-	0.00	0.94	1.27	1.08	1.55	1.47	2.79	3.20
Total Liabilities & Shareholders' Equity	5.69	9.41	6.11	12	9.88	18	40	25	48	47	69
Total Liabilities	8.64	5.37	3.11	3.53	4.50	5.61	6.18	7.26	8.14	11	14
Total Current Liabilities	6.83	4.78	2.48	2.92	3.12	3.71	4.35	5.07	6.02	7.68	11
Accounts Payable	2.52	2.07	2.46	2.90	3.12	3.71	4.35	5.07	6.02	7.68	11
Total Noncurrent Liabilities	1.81	0.59	0.62	0.61	1.38	1.91	1.83	2.19	2.12	3.04	3.49
Noncurrent Employee Benefit Liabilities	0.71	0.59	0.62	0.61	0.73	0.91	1.05	1.00	1.08	1.25	1.27
Other Noncurrent Operating Liabilities	-	-	-	0.00	0.65	1.00	0.78	1.20	1.04	1.80	2.22
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-2.95	4.05	2.73	8.76	5.38	12	34	17	40	36	55
Total Preferred & Common Equity	-2.95	4.05	2.73	8.76	5.38	12	34	17	40	36	55
Preferred Stock	0.00	-	0.00	0.00	0.00	-	-	0.00	0.00	0.00	0.00
Total Common Equity	-2.95	4.05	2.73	8.76	5.38	12	34	17	40	36	55
Common Stock	120	136	143	156	163	180	217	219	261	290	357
Retained Earnings	-123	-132	-140	-148	-158	-168	-183	-202	-222	-254	-302

This table presents InspireMD's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	50	42	56	50	39	33	78	56
Total Current Assets	47	39	52	46	32	25	70	49
Cash & Equivalents	14	9.39	28	16	12	12	63	11
Short-Term Investments	29	25	19	25	14	7.87	0.00	30
Note & Lease Receivable	0.36	0.48	0.45	0.74	0.76	0.50	0.48	0.41
Accounts Receivable	1.05	1.19	1.31	1.53	1.58	1.59	1.96	2.38
Inventories, net	1.85	2.36	2.21	2.45	2.82	3.05	3.61	3.04
Prepaid Expenses	0.48	0.53	0.72	1.28	0.89	0.95	0.95	1.20
Plant, Property, & Equipment, net	0.91	1.19	1.60	1.95	2.74	3.10	3.40	3.65
Total Noncurrent Assets	2.39	2.33	2.22	2.14	3.79	4.78	4.68	4.23
Employee Benefit Assets	0.85	0.97	0.96	1.00	1.14	1.28	1.33	1.19
Other Noncurrent Operating Assets	1.54	1.37	1.26	1.15	2.66	3.50	3.35	3.04
Total Liabilities & Shareholders' Equity	50	42	56	50	39	33	78	56
Total Liabilities	6.76	6.94	8.90	9.13	10	13	14	13
Total Current Liabilities	4.69	4.88	6.97	7.27	7.37	9.07	11	9.44
Accounts Payable	4.69	4.88	6.97	7.27	7.37	9.07	11	9.44
Total Noncurrent Liabilities	2.07	2.06	1.93	1.87	2.96	4.03	3.54	3.41
Noncurrent Employee Benefit Liabilities	1.01	1.15	1.15	1.18	1.32	1.52	1.18	1.37
Other Noncurrent Operating Liabilities	1.06	0.91	0.79	0.68	1.64	2.51	2.37	2.04
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	43	35	47	41	28	20	64	44
Total Preferred & Common Equity	43	35	47	41	28	20	64	44
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	43	35	47	41	28	20	64	44
Common Stock	259	264	283	286	293	298	355	360
Retained Earnings	-216	-229	-236	-244	-265	-278	-291	-316

This table displays calculated financial ratios and metrics derived from InspireMD's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	7,785,268.00	1,432,542.00	7,465,889.00	37,604,035.00	3,632,857.00	36,954,755.00	8,077,047.00	8,335,606.00	21,549,639.00	26,083,763.00	42,370,995.00
DEI Adjusted Shares Outstanding	0.00	55.00	284.00	50,139.00	242,190.00	2,463,650.00	8,077,047.00	8,335,606.00	21,549,639.00	26,083,763.00	42,370,995.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-153,836.36	-27,482.39	-159.20	-41.46	-4.28	-1.85	-2.22	-0.92	-1.23	-1.15
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-18.03%	-18.01%	45.78%	30.42%	3.33%	-33.22%	80.89%	15.04%	20.00%	12.96%	28.11%
EBITDA Growth	38.90%	47.23%	-7.50%	12.64%	-39.08%	-3.76%	-42.29%	-25.56%	-7.35%	-61.40%	-52.36%
EBIT Growth	38.56%	46.79%	-7.15%	12.69%	-38.34%	-3.63%	-41.77%	-25.46%	-7.52%	-60.93%	-52.52%
NOPAT Growth	38.88%	47.20%	-7.64%	7.54%	-28.97%	-5.75%	-41.77%	-27.16%	-12.99%	-58.46%	-48.09%
Net Income Growth	37.90%	45.71%	0.27%	14.20%	-38.67%	-5.02%	-41.48%	-23.95%	-7.71%	-60.70%	-52.43%
EPS Growth	37.90%	45.71%	0.27%	14.20%	71.21%	-5.02%	0.00%	0.00%	65.11%	7.32%	0.00%
Operating Cash Flow Growth	40.11%	35.37%	-8.49%	6.46%	-28.98%	7.43%	-45.47%	-17.65%	-5.37%	-33.54%	-60.52%
Free Cash Flow Firm Growth	38.34%	41.16%	-5.92%	7.34%	-35.92%	6.06%	-367.26%	86.59%	41.90%	-870.29%	-40.32%
Invested Capital Growth	-397.40%	17.17%	10.37%	12.41%	78.91%	-267.94%	4,566.39%	-40.72%	-96.25%	203.14%	-31.68%
Revenue Q/Q Growth	-13.29%	-9.29%	22.77%	-0.33%	5.41%	-25.60%	37.34%	-6.41%	13.44%	2.76%	15.43%
EBITDA Q/Q Growth	11.02%	6.54%	7.32%	-5.98%	-5.26%	-11.04%	-1.41%	-4.23%	-2.70%	-13.48%	-5.50%
EBIT Q/Q Growth	11.05%	6.36%	7.14%	-5.63%	-5.25%	-10.68%	-1.47%	-4.26%	-2.71%	-13.40%	-5.60%
NOPAT Q/Q Growth	11.25%	6.33%	7.27%	-11.04%	-3.15%	-13.22%	-1.47%	-5.68%	-4.30%	-11.89%	-5.79%
Net Income Q/Q Growth	11.05%	6.48%	8.35%	-10.94%	-3.55%	-14.01%	-1.66%	-4.22%	-2.89%	-13.35%	-5.60%
EPS Q/Q Growth	11.05%	6.48%	8.35%	-10.94%	23.08%	-14.01%	0.00%	-3.98%	-43.86%	-55.10%	7.32%
Operating Cash Flow Q/Q Growth	19.86%	4.29%	1.29%	-0.37%	2.34%	-7.48%	-5.60%	-1.93%	-6.38%	-13.34%	-7.98%
Free Cash Flow Firm Q/Q Growth	24.56%	7.17%	-0.52%	1.31%	4.38%	-13.85%	4.29%	31.54%	-172.18%	-12.80%	-5.16%
Invested Capital Q/Q Growth	-17.47%	-35.21%	28.02%	-110.51%	-117.66%	-221.11%	-10.31%	-28.85%	84.56%	52.69%	39.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	-12.81%	5.39%	21.19%	27.63%	20.32%	3.34%	16.77%	21.60%	29.12%	21.49%	29.50%
EBITDA Margin	-619.22%	-398.52%	-293.88%	-196.83%	-264.93%	-411.63%	-323.80%	-353.41%	-316.18%	-451.79%	-537.33%
Operating Margin	-627.06%	-403.80%	-298.15%	-211.36%	-263.80%	-417.71%	-327.39%	-361.88%	-340.74%	-478.00%	-552.56%
EBIT Margin	-629.65%	-408.61%	-300.33%	-201.06%	-269.18%	-417.71%	-327.39%	-357.05%	-319.92%	-455.79%	-542.63%
Profit (Net Income) Margin	-674.68%	-446.73%	-305.61%	-201.06%	-269.82%	-424.31%	-331.88%	-357.59%	-320.97%	-456.63%	-543.33%
Tax Burden Percent	100.03%	100.01%	100.32%	100.00%	100.24%	100.04%	100.30%	100.15%	100.33%	100.18%	100.13%
Interest Burden Percent	107.12%	109.32%	101.44%	100.00%	100.00%	101.54%	101.07%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-97.89%	-76.40%	-223.58%	-2,434.05%	-2,847.87%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-60.43%	-11.58%	-200.15%	-2,410.83%	-2,816.23%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	32.60%	3.78%	153.57%	2,349.37%	2,740.99%
Return on Equity (ROE)	543.69%	-1,539.76%	-239.51%	-123.09%	-141.95%	-120.19%	-65.29%	-72.62%	-70.01%	-84.68%	-106.88%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-150.09%	-25.27%	-38.03%	-2,534.83%	-2,810.23%
Operating Return on Assets (OROA)	-169.60%	-102.48%	-106.88%	-78.72%	-90.36%	-75.06%	-51.20%	-57.37%	-54.92%	-67.65%	-83.85%
Return on Assets (ROA)	-181.73%	-112.04%	-108.76%	-78.72%	-90.58%	-76.25%	-51.90%	-57.46%	-55.10%	-67.77%	-83.96%
Return on Common Equity (ROCE)	543.69%	-1,539.76%	-230.20%	-120.22%	-141.95%	-120.19%	-65.29%	-72.62%	-70.01%	-84.68%	-106.88%
Return on Equity Simple (ROE_SIMPLE)	529.02%	-209.17%	-309.42%	-82.62%	-186.51%	-86.69%	-44.49%	-106.31%	-50.42%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-5.35	-5.76	-5.33	-6.87	-7.27	-10	-13	-15	-23	-35
NOPAT Margin	-438.94%	-282.66%	-208.71%	-147.95%	-184.66%	-292.39%	-229.17%	-253.32%	-238.52%	-334.60%	-386.79%
Net Nonoperating Expense Percent (NNEP)	237.48%	-218.45%	-62.62%	-29.21%	-42.54%	-36.10%	-37.46%	-64.82%	-23.44%	-23.22%	-31.64%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-37.47%	-64.99%	-62.92%
Cost of Revenue to Revenue	112.81%	94.61%	78.81%	72.37%	79.68%	96.66%	83.23%	78.40%	70.88%	78.51%	70.50%
SG&A Expenses to Revenue	276.49%	263.99%	187.76%	134.13%	140.34%	246.56%	164.74%	161.59%	178.95%	218.38%	230.62%
R&D to Revenue	157.66%	68.16%	46.22%	42.63%	79.39%	89.86%	114.75%	151.03%	128.62%	194.52%	167.09%
Operating Expenses to Revenue	614.24%	409.19%	319.34%	238.99%	284.12%	421.05%	344.16%	383.48%	369.86%	499.49%	582.06%
Earnings before Interest and Taxes (EBIT)	-15	-7.74	-8.29	-7.24	-10	-10	-15	-18	-20	-32	-49
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-7.55	-8.11	-7.09	-9.86	-10	-15	-18	-20	-32	-48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.89	0.35	0.68	0.73	1.04	0.73	0.41	1.53	1.90	1.37
Price to Tangible Book Value (P/TBV)	0.00	0.89	0.35	0.68	0.73	1.04	0.73	0.41	1.53	1.90	1.37
Price to Revenue (P/Rev)	2.97	1.89	0.35	1.66	1.05	5.07	5.43	1.39	9.76	9.79	8.40
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.58	0.20	45.04	23.44	21.42
Enterprise Value to Revenue (EV/Rev)	3.83	0.00	0.00	0.00	0.00	0.00	2.76	0.49	3.47	4.85	2.36
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.78	0.66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	-0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.80	-2.59	-1.21	-1.11	-1.05	-1.03	-0.54	-0.33	-0.77	-0.97	-0.97
Leverage Ratio	-2.99	13.74	2.20	1.56	1.57	1.58	1.26	1.26	1.27	1.25	1.27
Compound Leverage Factor	-3.20	15.02	2.23	1.56	1.57	1.60	1.27	1.26	1.27	1.25	1.27
Debt to Total Capital	227.98%	39.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	180.23%	39.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	47.74%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	9.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-127.98%	60.15%	90.87%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.37	-0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-0.14	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.52	-0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-0.20	0.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-38.26	-21.25	-35.49	-16.62	-24.21	-12.90	-4.21	-12.33	-2.33	-5.00	-4.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	3.89%	2.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.68	1.81	2.08	3.91	2.51	4.14	8.53	4.21	7.34	5.28	5.74
Quick Ratio	0.56	1.69	1.84	3.49	2.08	3.58	3.08	1.16	6.89	4.80	5.30
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9.38	-5.52	-5.84	-5.42	-7.36	-6.92	-32	-4.33	-2.52	-24	-34
Operating Cash Flow to CapEx	-72,475.00%	-15,295.92%	-3,151.55%	-11,352.24%	-3,454.23%	-13,759.09%	-3,840.12%	-3,285.84%	-4,437.94%	-1,559.77%	-2,131.33%
Free Cash Flow to Firm to Interest Expense	-9.05	-7.65	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-11.19	-10.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-11.21	-10.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.27	0.25	0.36	0.39	0.34	0.18	0.16	0.16	0.17	0.15	0.15
Accounts Receivable Turnover	4.44	4.98	5.53	5.30	4.84	3.83	5.29	4.58	4.37	4.15	4.80
Inventory Turnover	1.95	2.86	4.21	3.13	2.50	1.81	2.92	2.93	2.36	2.35	2.12
Fixed Asset Turnover	4.22	4.45	6.46	8.03	7.69	5.00	8.32	6.68	6.28	4.09	3.02
Accounts Payable Turnover	0.74	0.78	0.96	0.97	0.99	0.70	0.93	0.86	0.79	0.80	0.69
Days Sales Outstanding (DSO)	82.16	73.33	66.03	68.87	75.48	95.40	69.02	79.69	83.47	87.90	76.02
Days Inventory Outstanding (DIO)	187.47	127.61	86.64	116.74	145.88	201.42	124.79	124.43	154.66	155.07	172.01
Days Payable Outstanding (DPO)	490.43	466.74	379.68	375.15	369.92	518.17	392.81	423.93	460.19	454.28	530.20
Cash Conversion Cycle (CCC)	-220.79	-265.80	-227.01	-189.54	-148.57	-221.35	-199.00	-219.81	-222.07	-211.30	-282.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.96	-0.79	-0.71	-0.62	-0.13	-0.48	22	13	0.48	1.45	0.99
Invested Capital Turnover	-4.03	-2.17	-3.68	-5.42	-9.90	-8.11	0.43	0.30	0.94	7.27	7.36
Increase / (Decrease) in Invested Capital	-0.76	0.16	0.08	0.09	0.49	-0.35	22	-8.77	-12	0.97	-0.46
Enterprise Value (EV)	8.84	-1.25	-2.48	-3.41	-1.59	-0.05	12	2.53	22	34	21
Market Capitalization	6.85	3.58	0.96	5.98	3.92	13	24	7.16	61	69	75
Book Value per Share	($0.38)	$2.82	$0.37	$0.23	$1.48	$0.33	$4.15	$2.09	$1.83	$1.38	$1.30
Tangible Book Value per Share	($0.38)	$2.82	$0.37	$0.23	$1.48	$0.33	$4.15	$2.09	$1.83	$1.38	$1.30
Total Capital	2.30	6.73	3.00	8.76	5.38	12	34	17	40	36	55
Total Debt	5.25	2.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	1.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	1.99	-4.84	-3.71	-9.38	-5.51	-13	-12	-4.63	-39	-35	-54
Capital Expenditures (CapEx)	0.02	0.05	0.26	0.07	0.28	0.07	0.34	0.47	0.37	1.40	1.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.31	-0.98	-1.04	-0.89	-0.82	-1.01	21	12	-0.88	-1.79	-3.45
Debt-free Net Working Capital (DFNWC)	1.95	6.53	2.67	8.50	4.70	12	33	16	38	33	51
Net Working Capital (NWC)	-2.20	3.85	2.67	8.50	4.70	12	33	16	38	33	51
Net Nonoperating Expense (NNE)	5.45	3.11	2.68	1.91	3.17	3.28	4.62	5.39	5.12	8.55	14
Net Nonoperating Obligations (NNO)	1.99	-4.84	-3.71	-9.38	-5.51	-13	-12	-4.63	-39	-35	-54
Total Depreciation and Amortization (D&A)	0.24	0.19	0.18	0.15	0.16	0.15	0.16	0.19	0.23	0.28	0.48
Debt-free, Cash-free Net Working Capital to Revenue	-56.71%	-51.85%	-37.56%	-24.58%	-22.01%	-40.68%	461.47%	224.79%	-14.25%	-25.60%	-38.45%
Debt-free Net Working Capital to Revenue	84.29%	344.98%	96.81%	236.02%	126.18%	468.17%	728.52%	314.37%	614.65%	468.58%	565.31%
Net Working Capital to Revenue	-95.32%	203.48%	96.81%	236.02%	126.18%	468.17%	728.52%	314.37%	614.65%	468.58%	565.31%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($36,585,937.50)	($155,662.50)	($26,235.00)	($247.50)	($72.00)	($6.90)	($2.03)	($2.35)	($0.82)	($0.76)	($0.76)
Adjusted Weighted Average Basic Shares Outstanding	1.00	56.00	2.23K	55.85K	289.26K	7.86M	8.32M	7.87M	24.27M	41.93M	64.33M
Adjusted Diluted Earnings per Share	($36,585,937.50)	($155,662.50)	($26,235.00)	($247.50)	($72.00)	($6.90)	($2.03)	$0.00	($0.82)	($0.76)	($0.76)
Adjusted Weighted Average Diluted Shares Outstanding	1.00	56.00	2.23K	55.85K	289.26K	7.86M	8.32M	8.33M	24.27M	41.93M	64.33M
Adjusted Basic & Diluted Earnings per Share	($36,585,937.50)	($155,662.50)	($26,235.00)	($247.50)	($72.00)	($6.90)	($2.03)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	54.00	497.00	30.77K	139.33K	1.51M	7.35M	8.33M	23.46M	29.69M	46.80M
Normalized Net Operating Profit after Tax (NOPAT)	-9.45	-5.35	-5.76	-5.33	-6.87	-7.27	-10	-13	-15	-23	-35
Normalized NOPAT Margin	-409.18%	-282.66%	-208.71%	-147.95%	-184.66%	-292.39%	-229.17%	-253.32%	-238.52%	-334.60%	-386.79%
Pre Tax Income Margin	-674.50%	-446.67%	-304.64%	-201.06%	-269.18%	-424.14%	-330.88%	-357.05%	-319.92%	-455.79%	-542.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.04	-10.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-9.79	-7.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-14.06	-10.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-9.80	-7.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from InspireMD's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	21,195,103.00	21,549,639.00	23,456,590.00	24,929,825.00	25,706,671.00	26,083,763.00	29,689,857.00	30,635,346.00	41,720,662.00	42,370,995.00	46,801,561.00
DEI Adjusted Shares Outstanding	21,195,103.00	21,549,639.00	23,456,590.00	24,929,825.00	25,706,671.00	26,083,763.00	29,689,857.00	30,635,346.00	41,720,662.00	42,370,995.00	46,801,561.00
DEI Earnings Per Adjusted Shares Outstanding	-0.24	-0.25	-0.30	-0.32	-0.31	-0.35	-0.38	-0.43	-0.30	-0.28	-0.29
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.74%	71.64%	21.95%	5.46%	16.32%	10.68%	1.19%	2.24%	39.39%	61.57%	122.24%
EBITDA Growth	-14.31%	-10.83%	-65.75%	-56.27%	-52.73%	-71.24%	-58.95%	-66.31%	-60.87%	-27.82%	-22.33%
EBIT Growth	-14.33%	-10.86%	-65.23%	-55.78%	-52.38%	-70.69%	-58.79%	-66.28%	-61.06%	-28.34%	-22.60%
NOPAT Growth	-22.32%	-17.67%	-69.23%	-55.41%	-50.06%	-61.28%	-54.57%	-57.62%	-54.23%	-29.01%	-21.97%
Net Income Growth	-14.33%	-11.56%	-65.23%	-55.78%	-52.38%	-69.73%	-58.79%	-66.28%	-61.06%	-28.20%	-22.60%
EPS Growth	74.14%	116.13%	60.38%	8.33%	-6.67%	-270.00%	204.76%	-18.18%	-6.25%	35.29%	-172.73%
Operating Cash Flow Growth	20.79%	-30.74%	-4.82%	-30.95%	-40.98%	-61.60%	-73.62%	-91.39%	-51.46%	-38.44%	-40.32%
Free Cash Flow Firm Growth	383.27%	54.70%	-70.22%	-88.35%	-148.17%	-191.61%	-418.47%	-1,071.22%	-34.54%	-6.27%	-4.69%
Invested Capital Growth	-98.56%	-96.25%	-87.64%	-106.20%	266.41%	203.14%	98.68%	317.25%	-25.08%	-31.68%	-9.38%
Revenue Q/Q Growth	-5.64%	13.17%	-14.20%	15.09%	4.08%	7.68%	-21.55%	16.29%	41.90%	24.81%	7.91%
EBITDA Q/Q Growth	-2.01%	-3.11%	-31.90%	-12.64%	0.29%	-15.60%	-22.43%	-17.85%	3.56%	8.15%	-17.18%
EBIT Q/Q Growth	-1.99%	-3.13%	-31.69%	-12.47%	0.24%	-15.53%	-22.50%	-17.78%	3.37%	7.95%	-17.02%
NOPAT Q/Q Growth	-6.10%	-3.00%	-27.65%	-11.41%	-2.45%	-10.69%	-22.34%	-13.60%	-0.25%	7.41%	-15.67%
Net Income Q/Q Growth	-1.99%	-4.38%	-30.10%	-12.47%	0.24%	-16.27%	-21.71%	-17.78%	3.37%	7.45%	-16.39%
EPS Q/Q Growth	37.50%	166.67%	-310.00%	-4.76%	27.27%	-6.25%	229.41%	-18.18%	34.62%	35.29%	-45.45%
Operating Cash Flow Q/Q Growth	-21.59%	-3.31%	-21.24%	14.02%	-30.91%	-18.42%	-30.25%	5.22%	-3.60%	-8.25%	-32.02%
Free Cash Flow Firm Q/Q Growth	49.60%	-40.15%	-65.06%	-62.77%	-718.65%	-13.83%	-21.47%	-13.54%	14.30%	10.09%	-19.66%
Invested Capital Q/Q Growth	-95.99%	84.56%	137.87%	-135.18%	337.25%	52.69%	55.90%	-61.53%	-18.18%	39.24%	106.77%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	28.15%	28.68%	19.33%	19.03%	22.87%	24.06%	19.10%	17.60%	34.24%	37.47%	20.22%
EBITDA Margin	-329.05%	-299.77%	-460.82%	-451.01%	-432.04%	-463.83%	-723.87%	-733.63%	-498.61%	-366.94%	-398.47%
Operating Margin	-362.40%	-329.81%	-490.67%	-474.99%	-467.51%	-480.61%	-749.51%	-732.23%	-517.28%	-383.74%	-411.36%
EBIT Margin	-332.78%	-303.24%	-465.39%	-454.80%	-435.91%	-467.68%	-730.28%	-739.65%	-503.69%	-371.48%	-402.85%
Profit (Net Income) Margin	-332.78%	-306.93%	-465.39%	-454.80%	-435.91%	-470.70%	-730.28%	-739.65%	-503.69%	-373.48%	-402.85%
Tax Burden Percent	100.00%	101.22%	100.00%	100.00%	100.00%	100.65%	100.00%	100.00%	100.00%	100.54%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-152.53%	-216.41%	-430.51%	-721.69%	-3,695.76%	-2,447.32%	-2,171.24%	-15,444.53%	-3,393.68%	-1,977.80%	-1,450.86%
ROIC Less NNEP Spread (ROIC-NNEP)	-147.29%	-210.28%	-420.86%	-716.83%	-3,691.04%	-2,440.22%	-2,160.76%	-15,432.39%	-3,386.79%	-1,970.37%	-1,439.32%
Return on Net Nonoperating Assets (RNNOA)	106.14%	161.35%	331.20%	670.47%	3,638.34%	2,378.01%	2,045.08%	15,324.38%	3,333.48%	1,917.72%	1,353.19%
Return on Equity (ROE)	-46.39%	-55.07%	-99.31%	-51.21%	-57.42%	-69.32%	-126.16%	-120.15%	-60.19%	-60.08%	-97.67%
Cash Return on Invested Capital (CROIC)	38.33%	-38.03%	-171.50%	0.00%	-3,584.57%	-2,534.83%	-1,614.03%	-3,554.04%	-3,926.49%	-2,810.23%	-1,685.11%
Operating Return on Assets (OROA)	-46.63%	-52.05%	-97.32%	-54.65%	-59.17%	-69.41%	-127.18%	-117.45%	-60.77%	-57.41%	-91.87%
Return on Assets (ROA)	-46.63%	-52.69%	-97.32%	-54.65%	-59.17%	-69.86%	-127.18%	-117.45%	-60.77%	-57.71%	-91.87%
Return on Common Equity (ROCE)	-46.39%	-55.07%	-99.31%	-51.21%	-57.42%	-69.32%	-126.16%	-120.15%	-60.19%	-60.08%	-97.67%
Return on Equity Simple (ROE_SIMPLE)	-44.75%	0.00%	-64.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.95	-4.07	-5.19	-5.78	-5.92	-6.56	-8.02	-9.11	-9.14	-8.46	-9.78
NOPAT Margin	-253.68%	-230.87%	-343.47%	-332.49%	-327.26%	-336.42%	-524.66%	-512.56%	-362.10%	-268.62%	-287.95%
Net Nonoperating Expense Percent (NNEP)	-5.24%	-6.14%	-9.65%	-4.86%	-4.72%	-7.11%	-10.47%	-12.14%	-6.88%	-7.43%	-11.54%
Return On Investment Capital (ROIC_SIMPLE)	-	-10.29%	-14.79%	-12.36%	-14.32%	-18.17%	-28.30%	-45.02%	-14.25%	-15.32%	-22.43%
Cost of Revenue to Revenue	71.85%	71.32%	80.68%	80.97%	77.13%	75.94%	80.90%	82.40%	65.76%	62.53%	79.78%
SG&A Expenses to Revenue	198.65%	168.60%	254.40%	215.35%	192.76%	216.93%	323.28%	299.55%	233.37%	144.49%	138.96%
R&D to Revenue	135.60%	115.56%	173.73%	195.57%	216.30%	189.48%	265.47%	215.64%	144.07%	110.35%	140.17%
Operating Expenses to Revenue	390.55%	358.49%	509.99%	494.02%	490.39%	504.67%	768.61%	749.83%	551.53%	421.21%	431.58%
Earnings before Interest and Taxes (EBIT)	-5.18	-5.34	-7.03	-7.91	-7.89	-9.12	-11	-13	-13	-12	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.12	-5.28	-6.96	-7.84	-7.82	-9.04	-11	-13	-13	-12	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.60	1.53	1.58	1.33	1.67	1.90	2.82	3.44	1.57	1.37	1.75
Price to Tangible Book Value (P/TBV)	1.60	1.53	1.58	1.33	1.67	1.90	2.82	3.44	1.57	1.37	1.75
Price to Revenue (P/Rev)	12.67	9.76	8.58	9.47	10.10	9.79	11.37	9.84	12.93	8.40	7.03
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	101.58	45.04	19.04	0.00	30.02	23.44	23.81	57.73	52.24	21.42	16.96
Enterprise Value to Revenue (EV/Rev)	4.81	3.47	3.34	2.29	4.18	4.85	7.65	7.10	4.77	2.36	3.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	7.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.72	-0.77	-0.79	-0.94	-0.99	-0.97	-0.95	-0.99	-0.98	-0.97	-0.94
Leverage Ratio	1.20	1.27	1.28	1.17	1.19	1.25	1.27	1.33	1.22	1.27	1.32
Compound Leverage Factor	1.20	1.27	1.28	1.17	1.19	1.25	1.27	1.33	1.22	1.27	1.32
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.88	-1.33	-2.24	-1.14	-1.70	-3.39	-4.94	-8.98	-0.51	-2.46	-4.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.96	7.34	7.90	7.44	6.39	5.28	4.36	2.81	6.51	5.74	5.15
Quick Ratio	9.47	6.89	7.30	7.02	5.87	4.80	3.86	2.37	6.09	5.30	4.70
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	14	8.22	2.87	1.07	-6.61	-7.53	-9.14	-10	-8.90	-8.00	-9.57
Operating Cash Flow to CapEx	-4,211.46%	-1,970.28%	-2,596.92%	-916.63%	-1,353.92%	-2,170.42%	-2,449.03%	-1,446.70%	-2,624.01%	-2,347.99%	-6,359.28%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.14	0.17	0.21	0.12	0.14	0.15	0.17	0.16	0.12	0.15	0.23
Accounts Receivable Turnover	4.95	4.37	4.97	4.73	5.30	4.15	5.08	4.87	4.46	4.80	5.48
Inventory Turnover	2.44	2.36	2.34	2.57	2.46	2.35	2.13	2.12	1.93	2.12	2.66
Fixed Asset Turnover	6.14	6.28	6.25	5.32	4.78	4.09	3.58	3.01	2.91	3.02	3.40
Accounts Payable Turnover	0.92	0.79	1.03	0.85	0.88	0.80	0.90	0.70	0.65	0.69	0.93
Days Sales Outstanding (DSO)	73.77	83.47	73.37	77.17	68.90	87.90	71.86	74.88	81.90	76.02	66.64
Days Inventory Outstanding (DIO)	149.86	154.66	155.84	142.14	148.34	155.07	171.29	172.10	189.09	172.01	136.99
Days Payable Outstanding (DPO)	397.68	460.19	355.70	430.39	413.30	454.28	404.73	524.56	564.93	530.20	393.11
Cash Conversion Cycle (CCC)	-174.06	-222.07	-126.49	-211.08	-196.06	-211.30	-161.58	-277.59	-293.94	-282.18	-189.48
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.26	0.48	1.14	-0.40	0.95	1.45	2.26	0.87	0.71	0.99	2.05
Invested Capital Turnover	0.60	0.94	1.25	2.17	11.29	7.27	4.14	30.13	9.37	7.36	5.04
Increase / (Decrease) in Invested Capital	-18	-12	-8.06	-6.85	0.69	0.97	1.12	1.27	-0.24	-0.46	-0.21
Enterprise Value (EV)	26	22	22	15	28	34	54	50	37	21	35
Market Capitalization	69	61	56	62	69	69	80	70	101	75	76
Book Value per Share	$2.04	$1.83	$1.50	$1.88	$1.61	$1.38	$0.95	$0.66	$1.54	$1.30	$0.93
Tangible Book Value per Share	$2.04	$1.83	$1.50	$1.88	$1.61	$1.38	$0.95	$0.66	$1.54	$1.30	$0.93
Total Capital	43	40	35	47	41	36	28	20	64	55	44
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-43	-39	-34	-47	-40	-35	-26	-19	-63	-54	-42
Capital Expenditures (CapEx)	0.10	0.21	0.20	0.48	0.42	0.31	0.36	0.58	0.33	0.40	0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.96	-0.88	-0.32	-2.29	-1.27	-1.79	-1.31	-2.98	-3.83	-3.45	-2.42
Debt-free Net Working Capital (DFNWC)	42	38	34	45	39	33	25	16	60	51	39
Net Working Capital (NWC)	42	38	34	45	39	33	25	16	60	51	39
Net Nonoperating Expense (NNE)	1.23	1.34	1.84	2.13	1.97	2.62	3.14	4.04	3.57	3.30	3.90
Net Nonoperating Obligations (NNO)	-43	-39	-34	-47	-40	-35	-26	-19	-63	-54	-42
Total Depreciation and Amortization (D&A)	0.06	0.06	0.07	0.07	0.07	0.08	0.10	0.11	0.13	0.14	0.15
Debt-free, Cash-free Net Working Capital to Revenue	-17.55%	-14.25%	-4.88%	-34.80%	-18.66%	-25.60%	-18.63%	-42.16%	-49.21%	-38.45%	-22.30%
Debt-free Net Working Capital to Revenue	768.52%	614.65%	519.28%	683.39%	573.65%	468.58%	352.60%	232.03%	765.84%	565.31%	360.91%
Net Working Capital to Revenue	768.52%	614.65%	519.28%	683.39%	573.65%	468.58%	352.60%	232.03%	765.84%	565.31%	360.91%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	$0.10	($0.21)	($0.22)	($0.16)	($0.17)	($0.22)	($0.26)	($0.17)	($0.11)	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	33.98M	24.27M	34.24M	35.88M	48.37M	41.93M	49.99M	51.00M	73.47M	64.33M	83.80M
Adjusted Diluted Earnings per Share	($0.15)	$0.10	($0.21)	($0.22)	($0.16)	($0.17)	($0.22)	($0.26)	($0.17)	($0.11)	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	33.98M	24.27M	34.24M	35.88M	48.37M	41.93M	49.99M	51.00M	73.47M	64.33M	83.80M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	21.55M	23.46M	24.93M	25.71M	26.08M	29.69M	30.64M	41.72M	42.37M	46.80M	46.84M
Normalized Net Operating Profit after Tax (NOPAT)	-3.95	-4.07	-5.19	-5.78	-5.92	-6.56	-8.02	-9.11	-9.14	-8.46	-9.78
Normalized NOPAT Margin	-253.68%	-230.87%	-343.47%	-332.49%	-327.26%	-336.42%	-524.66%	-512.56%	-362.10%	-268.62%	-287.95%
Pre Tax Income Margin	-332.78%	-303.24%	-465.39%	-454.80%	-435.91%	-467.68%	-730.28%	-739.65%	-503.69%	-371.48%	-402.85%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

InspireMD Financials - Frequently Asked Questions

According to the most recent income statement we have on file, InspireMD's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

InspireMD's net income appears to be on an upward trend, with a most recent value of -$48.79 million in 2025, rising from -$15.59 million in 2015. The previous period was -$32.01 million in 2024. View InspireMD's forecast to see where analysts expect InspireMD to go next.

InspireMD's total operating income in 2025 was -$49.61 million, based on the following breakdown:

Total Gross Profit: $2.65 million
Total Operating Expenses: $52.26 million

Over the last 10 years, InspireMD's total revenue changed from $2.31 million in 2015 to $8.98 million in 2025, a change of 288.7%.

InspireMD's total liabilities were at $14.20 million at the end of 2025, a 32.5% increase from 2024, and a 64.4% increase since 2015.

In the past 10 years, InspireMD's cash and equivalents has ranged from $3.26 million in 2015 to $18.92 million in 2024, and is currently $8.94 million as of their latest financial filing in 2025.

Over the last 10 years, InspireMD's book value per share changed from -0.38 in 2015 to 1.30 in 2025, a change of -444.3%.

Related Companies

Financial statements for NYSE:NSPR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InspireMD (NSPR) Financials

Financials Breakdown Chart

InspireMD Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InspireMD (NSPR) Financials

Annual Income Statements for InspireMD

Quarterly Income Statements for InspireMD

Annual Cash Flow Statements for InspireMD

Quarterly Cash Flow Statements for InspireMD

Annual Balance Sheets for InspireMD

Quarterly Balance Sheets for InspireMD

Annual Metrics And Ratios for InspireMD

Quarterly Metrics And Ratios for InspireMD

Financials Breakdown Chart

InspireMD Financials - Frequently Asked Questions

When does InspireMD's fiscal year end?

How has InspireMD's net income changed over the last 10 years?

What is InspireMD's operating income?

How has InspireMD's revenue changed over the last 10 years?

How much debt does InspireMD have?

How much cash does InspireMD have?

How has InspireMD's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools